Early Crohn disease: a proposed definition for use in disease-modification trials

被引：106
|
作者：
Peyrin-Biroulet, Laurent [1 ]
Loftus, Edward V., Jr. [1 ]
Colombel, Jean-Frederic [2 ]
Sandborn, William J. [1 ]
机构：
[1] Mayo Clin, Div Gastroenterol & Hepatol, Inflammatory Bowel Dis Clin, Rochester, MN 55905 USA
[2] CHU Lille, Hop Claude Huriez, F-59037 Lille, France
来源：
GUT | 2010年 / 59卷 / 02期
关键词：
EARLY RHEUMATOID-ARTHRITIS; INFLAMMATORY-BOWEL-DISEASE; POPULATION-BASED COHORT; C-REACTIVE PROTEIN; NATURAL-HISTORY; COMPUTED-TOMOGRAPHY; CYTOKINE PRODUCTION; RADIATION-EXPOSURE; CLINICAL-TRIALS; OLMSTED COUNTY;
D O I：
10.1136/gut.2009.187120
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：141 / 147
页数：7
相关论文
共 50 条
  • [1] Development of the Paris Definition of Early Crohn's Disease for Disease-Modification Trials: Results of an International Expert Opinion Process
    Peyrin-Biroulet, Laurent
    Billioud, Vincent
    D'Haens, Geert
    Panaccione, Remo
    Feagan, Brian
    Panes, Julian
    Danese, Silvio
    Schreiber, Stefan
    Ogata, Haruhiko
    Hibi, Toshifumi
    Higgins, Peter D. R.
    Beaugerie, Laurent
    Chowers, Yehuda
    Louis, Edouard
    Steinwurz, Flavio
    Reinisch, Walter
    Rutgeerts, Paul
    Colombel, Jean-Frederic
    Travis, Simon
    Sandborn, William J.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2012, 107 (12) : 1770 - 1776
  • [2] Early intervention in Crohn's disease: towards disease modification trials
    Danese, Silvio
    Fiorino, Gionata
    Peyrin-Biroulet, Laurent
    GUT, 2017, 66 (12) : 2179 - 2187
  • [3] Applications of neuroimaging to disease-modification trials in Alzheimer's disease
    Fleisher, Adam S.
    Donohue, Michael
    Chen, Kewei
    Brewer, James B.
    Aisen, Paul S.
    BEHAVIOURAL NEUROLOGY, 2009, 21 (1-2) : 129 - 136
  • [4] Selecting End Points for Disease-Modification Trials in Inflammatory Bowel Disease: the SPIRIT Consensus From the IOIBD
    Le Berre, Catherine
    Peyrin-Biroulet, Laurent
    GASTROENTEROLOGY, 2021, 160 (05) : 1452 - 1460
  • [5] Preparing for Disease-Modification Trials in Degenerative Cerebellar Ataxias: Which Endpoints to Choose?
    Maas, Roderick P. P. W. M.
    MOVEMENT DISORDERS, 2023, 38 (06) : 917 - 923
  • [6] Endpoints for Clinical Trials Evaluating Disease Modification and Structural Damage in Adults with Crohn's Disease
    D'Haens, Geert R.
    Fedorak, Richard
    Lemann, Marc
    Feagan, Brian G.
    Kamm, Michael A.
    Cosnes, Jacques
    Rutgeerts, Paul J.
    Marteau, Philippe
    Travis, Simon
    Schoelmerich, Juergen
    Hanauer, Steven
    Sandborn, William J.
    INFLAMMATORY BOWEL DISEASES, 2009, 15 (10) : 1599 - 1604
  • [7] Early use of immunosuppressives or TNF antagonists for the treatment of Crohn's disease: time for a change
    Ordas, Ingrid
    Feagan, Brian G.
    Sandborn, William J.
    GUT, 2011, 60 (12) : 1754 - 1763
  • [8] Exploring the use of adalimumab for patients with moderate Crohn's disease: Subanalyses from induction and maintenance trials
    Sandborn, William J.
    Colombel, Jean-Frederic
    Panes, Julian
    Castillo, Majin
    Robinson, Anne M.
    Zhou, Qian
    Yang, Mei
    Thakkar, Roopal
    JOURNAL OF CROHNS & COLITIS, 2013, 7 (12) : 958 - 967
  • [9] The potential for disease modification in Crohn's disease
    Van Assche, Gert
    Vermeire, Severine
    Rutgeerts, Paul
    NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2010, 7 (02) : 79 - 85
  • [10] Early Use of Thiopurines or Methotrexate Reduces Major Abdominal and Perianal Surgery in Crohn's Disease
    Kariyawasam, Viraj C.
    Selinger, Christian P.
    Katelaris, Peter H.
    Jones, D. Brian
    McDonald, Charles
    Barr, Gavin
    Chapman, Grace
    Colliwshaw, James
    Lunney, Paul C.
    Middleton, Kate
    Wang, Rosy R.
    Huang, Tony
    Andrews, Jane
    Leong, Rupert W.
    INFLAMMATORY BOWEL DISEASES, 2014, 20 (08) : 1382 - 1390
12345